• Mayssam Nehme, Olivia Braillard, François Chappuis, Delphine S Courvoisier, Idris Guessous, and CoviCare Study Team.
• Geneva University Hospitals, Geneva, Switzerland (M.N., O.B.).
• Ann. Intern. Med. 2021 Sep 1; 174 (9): 125212601252-1260.

BackgroundWith millions of SARS-CoV-2 infections worldwide, increasing numbers of patients are coming forward with long-term clinical effects of the disease lasting several weeks to months.ObjectiveTo characterize symptoms 7 to 9 months after diagnosis of COVID-19.DesignSelf-reported surveys and semistructured telephone interviews at enrollment and 30 to 45 days and 7 to 9 months from diagnosis.SettingFrom 18 March to 15 May 2020, symptomatic persons who tested positive for SARS-CoV-2 at the Geneva University Hospitals were followed by CoviCare, a virtual, clinical, outpatient follow-up program. Persons were contacted again at 30 to 45 days and 7 to 9 months from diagnosis.ParticipantsPersons who were a part of the CoviCare program from 18 March to 15 May 2020.MeasurementsA standardized interview of symptoms consistent with COVID-19, with grading of intensity.ResultsOf the 629 participants in the study who completed the baseline interviews, 410 completed follow-up at 7 to 9 months after COVID-19 diagnosis; 39.0% reported residual symptoms. Fatigue (20.7%) was the most common symptom reported, followed by loss of taste or smell (16.8%), dyspnea (11.7%), and headache (10.0%).LimitationLimitations include generalizability and missing data for 34.8% of participants.ConclusionResidual symptoms after SARS-CoV-2 infection are common among otherwise young and healthy persons followed in an outpatient setting. These findings contribute to the recognition of long-term effects in a disease mostly counted by its death toll to date by promoting communication on postacute sequelae of SARS-CoV-2 and encouraging physicians to continue long-term monitoring of their patients.Primary Funding SourceNone.

29 keywords...

hide…